$RLMD News

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today

Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed

Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call

Relmada Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?